Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 29563144)

  • 1. Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders.
    Waldman SA; Camilleri M
    Gut; 2018 Aug; 67(8):1543-1552. PubMed ID: 29563144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases.
    Jarmuż A; Zielińska M; Storr M; Fichna J
    Neurogastroenterol Motil; 2015 Aug; 27(8):1057-68. PubMed ID: 25930667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome.
    Miner PB
    Expert Opin Pharmacother; 2018 Feb; 19(2):177-183. PubMed ID: 29376436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guanylate cyclase-C receptor activation: unexpected biology.
    Brierley SM
    Curr Opin Pharmacol; 2012 Dec; 12(6):632-40. PubMed ID: 23131468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog.
    Brancale A; Shailubhai K; Ferla S; Ricci A; Bassetto M; Jacob GS
    Pharmacol Res Perspect; 2017 Apr; 5(2):e00295. PubMed ID: 28357122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
    Castro J; Harrington AM; Hughes PA; Martin CM; Ge P; Shea CM; Jin H; Jacobson S; Hannig G; Mann E; Cohen MB; MacDougall JE; Lavins BJ; Kurtz CB; Silos-Santiago I; Johnston JM; Currie MG; Blackshaw LA; Brierley SM
    Gastroenterology; 2013 Dec; 145(6):1334-46.e1-11. PubMed ID: 23958540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
    Busby RW; Bryant AP; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Mahajan-Miklos S; Pierce CM; Solinga RM; Sun LJ; Tobin JV; Kurtz CB; Currie MG
    Eur J Pharmacol; 2010 Dec; 649(1-3):328-35. PubMed ID: 20863829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guanylate Cyclase C: A Current Hot Target, from Physiology to Pathology.
    Uranga JA; Castro M; Abalo R
    Curr Med Chem; 2018; 25(16):1879-1908. PubMed ID: 29210639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation.
    Silos-Santiago I; Hannig G; Eutamene H; Ustinova EE; Bernier SG; Ge P; Graul C; Jacobson S; Jin H; Liong E; Kessler MM; Reza T; Rivers S; Shea C; Tchernychev B; Bryant AP; Kurtz CB; Bueno L; Pezzone MA; Currie MG
    Pain; 2013 Sep; 154(9):1820-1830. PubMed ID: 23748116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology.
    Forte LR
    Regul Pept; 1999 May; 81(1-3):25-39. PubMed ID: 10395405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome.
    Love BL
    Am J Med; 2019 May; 132(5):572-575. PubMed ID: 30550753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linaclotide-a novel secretagogue in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
    Sharma S; Sharma T; Dhingra R; Tomar P; Singh S; Malhotra M; Bhardwaj TR
    Mini Rev Med Chem; 2013 Oct; 13(11):1685-90. PubMed ID: 24001336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guanylin peptides: cyclic GMP signaling mechanisms.
    Forte LR; Freeman RH; Krause WJ; London RM
    Braz J Med Biol Res; 1999 Nov; 32(11):1329-36. PubMed ID: 10559833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain.
    Hannig G; Tchernychev B; Kurtz CB; Bryant AP; Currie MG; Silos-Santiago I
    Front Mol Neurosci; 2014; 7():31. PubMed ID: 24795564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine.
    Ahsan MK; Tchernychev B; Kessler MM; Solinga RM; Arthur D; Linde CI; Silos-Santiago I; Hannig G; Ameen NA
    Physiol Rep; 2017 Jun; 5(11):. PubMed ID: 28592587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolutionary divergence of receptor guanylyl cyclase C has implications for preclinical models for receptor-directed therapeutics.
    Mishra V; Sharma K; Bose A; Maisonneuve P; Visweswariah SS
    J Biol Chem; 2024 Jan; 300(1):105505. PubMed ID: 38029963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.
    Tchernychev B; Ge P; Kessler MM; Solinga RM; Wachtel D; Tobin JV; Thomas SR; Lunte CE; Fretzen A; Hannig G; Bryant AP; Kurtz CB; Currie MG; Silos-Santiago I
    J Pharmacol Exp Ther; 2015 Oct; 355(1):48-56. PubMed ID: 26216942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis.
    Pitari GM
    Drug Des Devel Ther; 2013; 7():351-60. PubMed ID: 23637522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmembrane guanylate cyclase in intestinal pathophysiology.
    Steinbrecher KA; Cohen MB
    Curr Opin Gastroenterol; 2011 Mar; 27(2):139-45. PubMed ID: 21102322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uroguanylin and guanylate cyclase C in the human pancreas: expression and mutuality of ligand/receptor localization as indicators of intercellular paracrine signaling pathways.
    Kulaksiz H; Cetin Y
    J Endocrinol; 2001 Jul; 170(1):267-75. PubMed ID: 11431160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.